@geovana-araujo.bsky.social
Reposted
Outcomes of oral azacitidine and venetoclax in newly diagnosed AML. High responses in TP53 mut patients. www.vjhemonc.com/video/wmkfly...
Outcomes with an all-oral regimen of CC-486 and venetoclax in patients with newly diagnosed AML
Maria Amaya, MD, PhD, University of Colorado Anschutz Medical Campus, Aurora, CO, presents the results from a clinical study (NCT05287568)...
www.vjhemonc.com
June 18, 2025 at 3:59 PM
Outcomes of oral azacitidine and venetoclax in newly diagnosed AML. High responses in TP53 mut patients. www.vjhemonc.com/video/wmkfly...
Meet Otis, the first therapy dog on CU Anschutz specifically trained to assist patients with obsessive-compulsive disorder ⬇️
One Tail, Two Minds: A New Approach to OCD Treatment
How a master level clinician at The University of Colorado Anschutz and her trained therapy dog are advancing exposure treatment for OCD patients.
news.cuanschutz.edu
June 17, 2025 at 2:27 PM
Congrats!!!
Congratulations to Maria Amaya, MD, PhD, Assistant Professor of Medicine-Hematology (and CU HemeOnc Fellowship alumni) on being selected as one of the 2025 Translational Research Scholars. Each scholar receives research support over four years. #CUAnschutz #CUCancer
June 17, 2025 at 2:25 PM
Congrats!!!
Reposted
Reposted
Four CU Cancer Center members have been tapped to serve as ambassadors for its four main scientific and clinical research programs ⬇️
‘Building Bridges’: The CU Cancer Center Names Four Program Liaisons
Four CU Cancer Center members have been tapped to serve as ambassadors for its four main scientific and clinical research programs.
news.cuanschutz.edu
May 27, 2025 at 4:04 PM
Four CU Cancer Center members have been tapped to serve as ambassadors for its four main scientific and clinical research programs ⬇️